PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
21.62%
Revenue growth above 1.5x CRON.TO's 12.77%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
39.20%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
-255.04%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-255.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
102.01%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
60.99%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
101.35%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
16.05%
Share count expansion well above CRON.TO's 1.11%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
14.82%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-96.29%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-212.61%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6217.76%
3Y CAGR of 6217.76% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
103.53%
OCF/share CAGR of 103.53% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
112.04%
OCF/share CAGR of 112.04% while CRON.TO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
102.33%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
387.66%
10Y net income/share CAGR of 387.66% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
2084.63%
Net income/share CAGR of 2084.63% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
232.29%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
2867.95%
Equity/share CAGR of 2867.95% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
4806.10%
Equity/share CAGR of 4806.10% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1601.21%
3Y equity/share CAGR above 1.5x CRON.TO's 523.19%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
830.66%
AR growth well above CRON.TO's 15.26%. Michael Burry fears inflated revenue or higher default risk in the near future.
36.09%
Inventory growth well above CRON.TO's 9.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
95.84%
Asset growth above 1.5x CRON.TO's 1.37%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
66.82%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
19.54%
Debt growth far above CRON.TO's 4.70%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
38.52%
R&D growth of 38.52% while CRON.TO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
69.20%
SG&A growth well above CRON.TO's 22.18%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.